SinoBiomed Inc.'s Malaria Vaccine Granted European Patent

SHANGHAI, CHINA--(MARKET WIRE)--Jul 25, 2007 -- Sinobiomed Inc. ("Sinobiomed", "the Company") (OTC BB:SOBM.OB - News) is pleased to announce that the European Patent Office (EPO) has granted a patent for the malaria vaccine PfCP2.9 to which Sinobiomed has exclusive rights to develop, manufacture and sell through its 82 percent owned subsidiary, Shanghai Wanxing Bio-pharmaceuticals Co., Ltd. ("Shanghai Wanxing"). The EPO provides patent protection in up to 37 European countries.

Back to news